# Open Label Extension Study of HT-100 in Patients With DMD

> **NCT01978366** · PHASE2 · TERMINATED · sponsor: **Processa Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** HT-100

## Key facts

- **NCT ID:** NCT01978366
- **Lead sponsor:** Processa Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2016-04-30
- **Final completion:** 2016-04-30
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Dosing stopped
- **Last updated:** 2020-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01978366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01978366, "Open Label Extension Study of HT-100 in Patients With DMD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01978366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*